Donor lymphocyte infusion (DLI) is used after both myeloablative and non-myeloablative
stem-cell transplantation to treat and prevent relapse, to establish full donor chimerism, and …

Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with
acute leukemia. Unfortunately, many patients relapse and die of their disease even after …

Allogeneic stem cell transplantation (allo-SCT) is the preferred curative treatment for several
hematological malignancies. The efficacy of allo-SCT depends on the graft-versus-leukemia …

Donor lymphocyte infusion (DLI), pioneered in Jerusalem in January 1987, represents the
first proof of principle of the absolute efficacy of immunotherapy as a means of curing cancer …

The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusion
[DLI]) reinduces complete remission in a high percentage of patients with chronic myeloid …

The success of donor lymphocyte infusion (DLI) in treating chronic myeloid leukaemia that
had recurred after allogeneic haematopoietic stem cell transplantation provided direct …

Abstract Between 1991 and 1999, 44 leukemic patients received donor lymphocyte
infusions (DLIs) at our center (22 patients with chronic myelogenous leukemia [CML]; 10 …

A retrospective analysis was performed of 118 patients with hematologic malignancies who
received donor lymphocyte infusions (DLIs) after allogeneic stem cell transplantation …

Background Donor lymphocyte infusion (DLI) was used as salvage therapy in leukemia
relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), but existing …

We retrospectively compared the antileukemic effects of chemotherapy alone and
chemotherapy followed by modified donor lymphocyte infusion (DLI) in 82 patients with …